Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164

V Sacchi, R Mittermayr, J Hartinger… - Proceedings of the …, 2014 - National Acad Sciences
Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor (VEGF) gene
delivery failed to show efficacy. Major challenges include the need to precisely control in …

Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF 164

V Sacchi, R Mittermayr, J Hartinger… - Proceedings of the …, 2014 - cir.nii.ac.jp
抄録< jats: title> Significance</jats: title>< jats: p> Inducing the growth of new blood vessels
by specific factors is an attractive strategy to restore blood flow in ischemic tissues. Vascular …

Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF (164)

V Sacchi, R Mittermayr, J Hartinger… - Proceedings Of The …, 2014 - infoscience.epfl.ch
Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor (VEGF) gene
delivery failed to show efficacy. Major challenges include the need to precisely control in …

[PDF][PDF] Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164

V Sacchia, R Mittermayrb, J Hartingerb, MM Martinoc… - academia.edu
Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor (VEGF) gene
delivery failed to show efficacy. Major challenges include the need to precisely control in …

Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164.

V Sacchi, R Mittermayr, J Hartinger… - Proceedings of the …, 2014 - folia.unifr.ch
English Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor
(VEGF) gene delivery failed to show efficacy. Major challenges include the need to precisely …

[PDF][PDF] Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164

V Sacchia, R Mittermayrb, J Hartingerb, MM Martinoc… - core.ac.uk
Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor (VEGF) gene
delivery failed to show efficacy. Major challenges include the need to precisely control in …

Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164.

V Sacchi, R Mittermayr, J Hartinger, MM Martino… - Proceedings of the …, 2014 - sonar.ch
English Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor
(VEGF) gene delivery failed to show efficacy. Major challenges include the need to precisely …

Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164

V Sacchi, R Mittermayr, J Hartinger… - Proceedings of the …, 2014 - ui.adsabs.harvard.edu
Inducing the growth of new blood vessels by specific factors is an attractive strategy to
restore blood flow in ischemic tissues. Vascular endothelial growth factor (VEGF) is the …

Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164

V Sacchi, R Mittermayr, J Hartinger… - Proceedings of the …, 2014 - edoc.unibas.ch
Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor (VEGF) gene
delivery failed to show efficacy. Major challenges include the need to precisely control in …

Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164

V Sacchi, R Mittermayr, J Hartinger… - Proceedings of the …, 2014 - zora.uzh.ch
Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor (VEGF) gene
delivery failed to show efficacy. Major challenges include the need to precisely control in …